Fairvalue-Calculator Fairvalue-Calculator
EN DE

VACBF (VACBF) Fair Value & Analysis

Healthcare · US · Market cap $169M

Price$0.3247
Fair Value$0.1600
Upside-50.7%
Quality95/100
Evidence: Low Range $0.1100 – $0.2000

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

VACBF (VACBF) currently trades at $0.3247, while our model-based Fair Value estimate is $0.1600 — implying the stock looks roughly 50.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is VACBF (VACBF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.1600 versus a price of $0.3247 — about −51% (overvalued). Model-based estimate, not financial advice.
What is the fair value of VACBF?
Our 21-model fair value for VACBF is $0.1600 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.3247.
What is the quality score of VACBF?
VACBF has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.